Literature DB >> 21804357

The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.

Angela E Reeves1, Casey M Theriot, Ingrid L Bergin, Gary B Huffnagle, Patrick D Schloss, Vincent B Young.   

Abstract

Clostridium difficile infection (CDI) arises in the setting of antibiotic administration where disruption of the normal indigenous gut microbiota leads to susceptibility to C. difficile colonization and colitis. Using a murine model of CDI, we demonstrate that changes in the community structure of the indigenous gut microbiota are associated with the loss of colonization resistance against C. difficile. Several antibiotic regimens were tested in combination for the ability to overcome colonization resistance, including a five antibiotic cocktail consisting of kanamycin, gentamicin, colistin, metronidazole, and vancomycin administered in drinking water for three days, a single intraperitoneal dose of clindamycin or 10 days of cefoperazone in drinking water. Following antibiotic treatment animals were challenged with 105 colony forming units of C. difficile strain VPI 10463 via oral gavage. Animals that received the antibiotic cocktail and clindamycin prior to C. difficile challenge followed one of two clinical courses, either becoming clinically ill and moribund within 2-4 days post challenge, or remaining clinically well. Animals that became clinically ill developed histologically severe colitis. These histopathologic findings were significantly less severe in animals that remained clinically well. Analysis of 16S rRNA gene sequences retrieved from gut tissue at necropsy demonstrated that Proteobacteria dominated the gut microbiota in clinically ill animals. In contrast, the gut microbial community of clinically well animals more closely resembled untreated animals, which were dominated by members of the Firmicutes. All animals that received cefoperazone treatment prior to C. difficile challenge were clinically ill and moribund by 2-5 days post challenge in a dose dependent manner. The gut communities in these animals were dominated by C.difficile suggesting that cefoperazone treatment resulted in a greater loss in colonization resistance. Thus, the severity of colitis that arises in this system reflects the interplay between the expansion of C. difficile in the gut community and the ecologic dynamics of the indigenous microbial community as it recovers from antibiotic perturbation. We demonstrate that altering the balance of these two opposing processes alters clinical outcome and thus may lead to novel preventative and therapeutic approaches for CDI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21804357      PMCID: PMC3225775          DOI: 10.4161/gmic.2.3.16333

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  63 in total

1.  The Ribosomal Database Project (RDP-II): previewing a new autoaligner that allows regular updates and the new prokaryotic taxonomy.

Authors:  J R Cole; B Chai; T L Marsh; R J Farris; Q Wang; S A Kulam; S Chandra; D M McGarrell; T M Schmidt; G M Garrity; J M Tiedje
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

Review 2.  Bacterial contributions to mammalian gut development.

Authors:  Lora V Hooper
Journal:  Trends Microbiol       Date:  2004-03       Impact factor: 17.079

3.  Colonization resistance of the digestive tract in conventional and antibiotic-treated mice.

Authors:  D van der Waaij; J M Berghuis-de Vries
Journal:  J Hyg (Lond)       Date:  1971-09

4.  Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters.

Authors:  J G Bartlett; A B Onderdonk; R L Cisneros; D L Kasper
Journal:  J Infect Dis       Date:  1977-11       Impact factor: 5.226

5.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.

Authors:  Jacques Pépin; Louis Valiquette; Marie-Eve Alary; Philippe Villemure; Annick Pelletier; Karine Forget; Karine Pépin; Daniel Chouinard
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

6.  Interaction of Clostridium difficile and Escherichia coli with microfloras in continuous-flow cultures and gnotobiotic mice.

Authors:  K H Wilson; R Freter
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

7.  Modulation of cytotoxin production by Clostridium difficile in the intestinal tracts of gnotobiotic mice inoculated with various human intestinal bacteria.

Authors:  G Corthier; F Dubos; P Raibaud
Journal:  Appl Environ Microbiol       Date:  1985-01       Impact factor: 4.792

8.  "Collateral damage" from cephalosporin or quinolone antibiotic therapy.

Authors:  David L Paterson
Journal:  Clin Infect Dis       Date:  2004-05-15       Impact factor: 9.079

9.  Clostridium difficile in gnotobiotic mice.

Authors:  A B Onderdonk; R L Cisneros; J G Bartlett
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

10.  Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis.

Authors:  K H Wilson; J Silva; F R Fekety
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

View more
  147 in total

1.  The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.

Authors:  Andrew J McDermott; Kathryn E Higdon; Ryan Muraglia; John R Erb-Downward; Nicole R Falkowski; Roderick A McDonald; Vincent B Young; Gary B Huffnagle
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

Review 2.  Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection.

Authors:  L Patrick Schenck; Paul L Beck; Justin A MacDonald
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 3.  Considering the Immune System during Fecal Microbiota Transplantation for Clostridioides difficile Infection.

Authors:  Alyse L Frisbee; William A Petri
Journal:  Trends Mol Med       Date:  2020-02-17       Impact factor: 11.951

Review 4.  Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance.

Authors:  Robert A Britton; Vincent B Young
Journal:  Trends Microbiol       Date:  2012-05-15       Impact factor: 17.079

5.  Topical Antimicrobial Treatments Can Elicit Shifts to Resident Skin Bacterial Communities and Reduce Colonization by Staphylococcus aureus Competitors.

Authors:  Adam J SanMiguel; Jacquelyn S Meisel; Joseph Horwinski; Qi Zheng; Elizabeth A Grice
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Molecular detection of bacterial contamination in gnotobiotic rodent units.

Authors:  Christopher D Packey; Michael T Shanahan; Sayeed Manick; Maureen A Bower; Melissa Ellermann; Susan L Tonkonogy; Ian M Carroll; R Balfour Sartor
Journal:  Gut Microbes       Date:  2013-07-24

7.  Aging Dampens the Intestinal Innate Immune Response during Severe Clostridioides difficile Infection and Is Associated with Altered Cytokine Levels and Granulocyte Mobilization.

Authors:  Lisa Abernathy-Close; Michael G Dieterle; Kimberly C Vendrov; Ingrid L Bergin; Krishna Rao; Vincent B Young
Journal:  Infect Immun       Date:  2020-05-20       Impact factor: 3.441

Review 8.  Understanding Clostridium difficile Colonization.

Authors:  Monique J T Crobach; Jonathan J Vernon; Vivian G Loo; Ling Yuan Kong; Séverine Péchiné; Mark H Wilcox; Ed J Kuijper
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

Review 9.  Microbiota-mediated colonization resistance against intestinal pathogens.

Authors:  Charlie G Buffie; Eric G Pamer
Journal:  Nat Rev Immunol       Date:  2013-10-07       Impact factor: 53.106

10.  Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.

Authors:  Peter Warn; Pia Thommes; Abdul Sattar; David Corbett; Amy Flattery; Zuo Zhang; Todd Black; Lorraine D Hernandez; Alex G Therien
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.